Search company, investor...
Oxford BioMedica company logo

Oxford BioMedica

Founded Year




About Oxford BioMedica

Oxford BioMedica is a biopharmaceutical company that specializes in the development and commercialization of gene-based medicines.

Headquarters Location

Windrush Court Transport Way

Oxford, England, OX4 6LT,

United Kingdom

+44 (0) 1865 783 000

Missing: Oxford BioMedica's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Oxford BioMedica's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Oxford BioMedica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford BioMedica is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Oxford BioMedica Patents

Oxford BioMedica has filed 42 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Genetics
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Transcription factors, Immunology, Immune system, Oncology


Application Date


Grant Date



Related Topics

Clusters of differentiation, Transcription factors, Immunology, Immune system, Oncology



Latest Oxford BioMedica News

Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Mar 9, 2023

Fourth Quarter 2022 and Full Year Financial Results Net loss for the quarter ended December 31, 2022 was $(34.3) million or $(0.60) per share, compared to a net loss of $(33.6) million or $(0.59) per share for the same period in 2021. Net loss for the year ended December 31, 2022 was $(5.0) million or $(0.09) per share, compared to a net loss of $(95.8) million or $(1.73) per share for the same period in 2021. The decrease in net loss was primarily due to a gain of $131.2 million realized in connection with the Company’s sale of its manufacturing business to Oxford Biomedica in order to establish Oxford Biomedica Solutions (“OXB Solutions”), an AAV Innovation and Manufacturing Business, in the first quarter of 2022, partially offset by lower collaboration revenues in 2022. Collaboration revenues for the three and twelve months ended December 31, 2022 were $0.8 million and $3.2 million, respectively, as compared to $0.8 million and $34.0 million for the comparable periods in 2021. Collaboration revenues in 2022 consisted of revenue recognized under the Company’s stock purchase agreement with Pfizer compared with collaboration revenues in 2021, which were primarily the result of concluding the Company’s collaboration with Novartis. Total operating expenses for the three and twelve months ended December 31, 2022 were $35.3 million and $136.5 million, respectively, as compared to $34.4 million and $129.9 million for the comparable periods in 2021, and consisted of research and development expenses and general and administrative expenses. Research and development expenses for the three and twelve months ended December 31, 2022 were $27.2 million and $98.4 million, respectively, as compared to $23.6 million and $93.1 million for the comparable periods in 2021. Research and development expenses increased by $5.3 million in 2022 primarily due to increases in direct costs of $9.3 million related to pheEDIT and $3.9 million related to juMPStart, as we incurred costs to initiate sites and recruit patients. Additionally, there was a $5.8 million increase in direct research expenses related to our other development-stage programs, primarily due to higher spending on HMI-104. Partially offsetting these increases was a $15.6 million decrease in employee-related costs as a result of transferring employees to OXB Solutions in order to leverage the Company’s in-house manufacturing capabilities while establishing a 20% ownership stake and preferred customer status in the new business. General and administrative expenses for the three and twelve months ended December 31, 2022 were $8.1 million and $38.1 million, respectively, as compared to $10.8 million and $36.8 million for the comparable periods in 2021. General and administrative expenses increased in 2022 due primarily to professional fees associated with the establishment of OXB Solutions. As of December 31, 2022, Homology had approximately $175.0 million in cash, cash equivalents and short-term investments. Based on current projections, Homology expects current cash resources to fund operations into the fourth quarter of 2024. Upcoming Events 2023 ACMG Annual Clinical Genetics Meeting: March 14 - 18 About Homology Medicines, Inc. Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homology’s internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit Forward-Looking Statements This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our plans to engage in future collaborations and strategic partnerships; our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines; the sufficiency of our cash and cash equivalents to fund our operations; and our participation in upcoming presentations and conferences. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. - Financial Tables Follow -

Oxford BioMedica Frequently Asked Questions (FAQ)

  • When was Oxford BioMedica founded?

    Oxford BioMedica was founded in 1995.

  • Where is Oxford BioMedica's headquarters?

    Oxford BioMedica's headquarters is located at Windrush Court, Oxford.

  • What is Oxford BioMedica's latest funding round?

    Oxford BioMedica's latest funding round is PIPE - II.

  • Who are the investors of Oxford BioMedica?

    Investors of Oxford BioMedica include Serum Institute of India, Novo Holdings, Molten Ventures, Spark Ventures and University of Oxford.

  • Who are Oxford BioMedica's competitors?

    Competitors of Oxford BioMedica include Dicerna Pharmaceuticals, Stemline Therapeutics, DiaMedica, GenVec, Agile Therapeutics and 13 more.

Compare Oxford BioMedica to Competitors

Pique Therapeutics

Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Action Pharma

a biopharmaceutical company founded in 2000 and located in Denmark The company's main strategy is to bring drug candidates rapidly from pre-clinical development into clinical trials for subsequent partnering.The goal is to bring one drug candidate into clinical development per year and currently two lead candidates are in clinical development. The company plan to seek partners for late clinical development and commercialisation of the company's drug candidates after successful development in phase I or II by partnering with major biotech and pharmaceutical companies.


OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.


Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the Targestarline of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson's agents can be readily targeted to the molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company's intellectual property aims to enable the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which aims to enable the user to verify that the therapeutic compound has been delivered to the intended site.

Minerva Biotechnologies Logo
Minerva Biotechnologies

Minerva Biotechnologies developd biochips: nanoparticles coated with functionalized affinity surfaces. Minerva has developed user-friendly nanoparticles that the end user can utilize as a "black box technology". The nanoparticle system can be fully automated and a range of nanoparticles have been developed so that the readout is compatible with existing lab equipment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.